Defunct Company
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
7
NCT04652570
Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
Phase: Phase 1/2
Role: Lead Sponsor
Start: May 5, 2021
Completion: Aug 15, 2024
NCT05441826
Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)
Phase: Phase 2
Start: May 3, 2022
Completion: Oct 12, 2023
NCT06570434
Phase 1b/2a in SLE With Budoputug
Start: Jan 31, 2025
Completion: Apr 30, 2027